Rentosertib (ISM001-055), AI-discovered TNIK inhibitor

entry · p2026-09-06-147 · validated

enrolled 71 patients with IPF across 22 sites in China

tech: rentosertib
passes the definition as: generative models fit to omics and chemical data to pick the target (TNIK) and design the molecule
from: 2025-06-03
region: CN
domain: health
side: benefit
people: 71 patients with idiopathic pulmonary fibrosis (2025-06-03)
effect: 98.4 millilitres FVC (2025-06-03) — mean forced vital capacity gain of +98.4 mL at 60 mg once daily over 12 weeks, against −20.3 mL on placebo
reversible: yes
who holds the switch: owner:Insilico Medicine
attribution: named
source kind: primary
the statistic: The GENESIS-IPF phase 2a trial enrolled 71 IPF patients at 22 sites in China; at 12 weeks the 60 mg QD arm gained a mean +98.4 mL FVC against −20.3 mL on placebo. Published in Nature Medicine, 3 June 2025; the drug is now in phase 3 and is not approved.
source: https://insilico.com/news/tnrecuxsc1-insilico-announces-nature-medicine-publi
proposed by: researcher (opus), brief 2026-09-06, era-2024-2026
received: 2026-09-06T09:39:39-04:00
harvest report: impacts/harvest/2026-09-06-era-2024-2026.md

Rulings, in order

2026-09-06T09:39:47-04:00 · validatorpass — quote found on the fetched page (exact match; HTTP 200 text/html; charset=utf-8)
2026-09-06T09:59:36-04:00 · sessionseverity — a treatment in trial with a measured outcome

The proposal as it arrived (JSON)

{
 "id": "p2026-09-06-147",
 "received": "2026-09-06T09:39:39-04:00",
 "proposer": "researcher (opus), brief 2026-09-06, era-2024-2026",
 "kind": "entry",
 "sha": "21896086d03ebf74",
 "data": {
  "kind": "entry",
  "tech": "rentosertib",
  "tech_name": "Rentosertib (ISM001-055), AI-discovered TNIK inhibitor",
  "definition": "generative models fit to omics and chemical data to pick the target (TNIK) and design the molecule",
  "from": "2025-06-03",
  "region": "CN",
  "domain": "health",
  "side": "benefit",
  "people": {
   "n": 71,
   "unit": "patients with idiopathic pulmonary fibrosis",
   "date": "2025-06-03"
  },
  "effect": {
   "n": 98.4,
   "unit": "millilitres FVC",
   "date": "2025-06-03",
   "what": "mean forced vital capacity gain of +98.4 mL at 60 mg once daily over 12 weeks, against −20.3 mL on placebo"
  },
  "reversible": true,
  "switch": "owner:Insilico Medicine",
  "statistic": "The GENESIS-IPF phase 2a trial enrolled 71 IPF patients at 22 sites in China; at 12 weeks the 60 mg QD arm gained a mean +98.4 mL FVC against −20.3 mL on placebo. Published in Nature Medicine, 3 June 2025; the drug is now in phase 3 and is not approved.",
  "source": "https://insilico.com/news/tnrecuxsc1-insilico-announces-nature-medicine-publi",
  "quote": "enrolled 71 patients with IPF across 22 sites in China",
  "attribution": "named",
  "source_kind": "primary"
 },
 "from_file": "impacts/harvest/2026-09-06-era-2024-2026.md"
}